IL17A and Bloom syndrome: In terms of CD4+ T cells, IL-17+ CD4+ T cells and IFN-γ+ CD4+ T cells upregulated in the BLM model were effectively reduced by MSC treatment, regardless of the route of administration (Fig. 5B).